Molecular Recognition of Ternary Complexes: a New Dimension in the Structure-guided Design of Chemical Degraders

Overview

Journal Essays Biochem

Specialty Biochemistry

Date 2017 Nov 10

PMID 29118097

Citations 81

Authors

Scott J Hughes

Alessio Ciulli

Affiliations

Soon will be listed here.

Abstract

Molecular glues and bivalent inducers of protein degradation (also known as PROTACs) represent a fascinating new modality in pharmacotherapeutics: the potential to knockdown previously thought 'undruggable' targets at sub-stoichiometric concentrations in ways not possible using conventional inhibitors. Mounting evidence suggests these chemical agents, in concert with their target proteins, can be modelled as three-body binding equilibria that can exhibit significant cooperativity as a result of specific ligand-induced molecular recognition. Despite this, many existing drug design and optimization regimens still fixate on binary target engagement, in part due to limited structural data on ternary complexes. Recent crystal structures of protein complexes mediated by degrader molecules, including the first PROTAC ternary complex, underscore the importance of protein-protein interactions and intramolecular contacts to the mode of action of this class of compounds. These discoveries have opened the door to a new paradigm for structure-guided drug design: borrowing surface area and molecular recognition from nature to elicit cellular signalling.

Citing Articles

A paradigm shift: analytical ultracentrifugation as a multi-attribute platform method in targeted protein degradation.

Yarawsky A, Ronau J, Thibaudeau T, Ehlinger A, Chhor G, Hyman S Eur Biophys J. 2025; .

PMID: 39961810 DOI: 10.1007/s00249-025-01735-1.

Fragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR () Phosphatase.

Wu J, Baranowski M, Aleshin A, Isiorho E, Lambert L, De Backer L ACS Omega. 2025; 10(5):4912-4926.

PMID: 39959108 PMC: 11822521. DOI: 10.1021/acsomega.4c10321.

Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC).

Monsen P, Bommi P, Grigorescu A, Lauing K, Mao Y, Berardi P J Med Chem. 2025; 68(4):4961-4987.

PMID: 39946350 PMC: 11874035. DOI: 10.1021/acs.jmedchem.5c00026.

Single-Molecule-Based, Label-Free Monitoring of Molecular Glue Efficacies for Promoting Protein-Protein Interactions Using YaxAB Nanopores.

Ryu M, Oh S, Jeong K, Hwang S, Kim J, Chung M ACS Nano. 2024; 18(45):31451-31465.

PMID: 39482865 PMC: 11562796. DOI: 10.1021/acsnano.4c11436.

Mechanism of degrader-targeted protein ubiquitinability.

Crowe C, Nakasone M, Chandler S, Craigon C, Sathe G, Tatham M Sci Adv. 2024; 10(41):eado6492.

PMID: 39392888 PMC: 11468923. DOI: 10.1126/sciadv.ado6492.

References

Fischer E, Park E, Eck M, Thoma N . SPLINTS: small-molecule protein ligand interface stabilizers. Curr Opin Struct Biol. 2016; 37:115-22. PMC: 4834252. DOI: 10.1016/j.sbi.2016.01.004. View

Kissinger C, Parge H, Knighton D, Lewis C, Pelletier L, Tempczyk A . Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature. 1995; 378(6557):641-4. DOI: 10.1038/378641a0. View

Choi J, Chen J, Schreiber S, Clardy J . Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996; 273(5272):239-42. DOI: 10.1126/science.273.5272.239. View

Pommier Y, Marchand C . Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov. 2011; 11(1):25-36. PMC: 7380715. DOI: 10.1038/nrd3404. View

Bartlett J, Dredge K, Dalgleish A . The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4(4):314-22. DOI: 10.1038/nrc1323. View

Cyrus K, Wehenkel M, Choi E, Han H, Lee H, Swanson H . Impact of linker length on the activity of PROTACs. Mol Biosyst. 2010; 7(2):359-64. PMC: 3835402. DOI: 10.1039/c0mb00074d. View

Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P . Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003; 302(5647):1056-60. DOI: 10.1126/science.1089591. View

Jin L, Harrison S . Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A. 2002; 99(21):13522-6. PMC: 129706. DOI: 10.1073/pnas.212504399. View

Gray W, Kepinski S, Rouse D, Leyser O, Estelle M . Auxin regulates SCF(TIR1)-dependent degradation of AUX/IAA proteins. Nature. 2001; 414(6861):271-6. DOI: 10.1038/35104500. View

10.

Brown E, Albers M, Shin T, Ichikawa K, Keith C, Lane W . A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369(6483):756-8. DOI: 10.1038/369756a0. View

11.

Kronke J, Fink E, Hollenbach P, MacBeth K, Hurst S, Udeshi N . Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015; 523(7559):183-188. PMC: 4853910. DOI: 10.1038/nature14610. View

12.

Milroy L, Grossmann T, Hennig S, Brunsveld L, Ottmann C . Modulators of protein-protein interactions. Chem Rev. 2014; 114(9):4695-748. DOI: 10.1021/cr400698c. View

13.

Petzold G, Fischer E, Thoma N . Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016; 532(7597):127-30. DOI: 10.1038/nature16979. View

14.

Thiel P, Kaiser M, Ottmann C . Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew Chem Int Ed Engl. 2012; 51(9):2012-8. DOI: 10.1002/anie.201107616. View

15.

Buckley D, Gustafson J, Van Molle I, Roth A, Tae H, Gareiss P . Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew Chem Int Ed Engl. 2012; 51(46):11463-7. PMC: 3519281. DOI: 10.1002/anie.201206231. View

16.

Beddell C, Goodford P, Norrington F, Wilkinson S, Wootton R . Compounds designed to fit a site of known structure in human haemoglobin. Br J Pharmacol. 1976; 57(2):201-9. PMC: 1667110. DOI: 10.1111/j.1476-5381.1976.tb07468.x. View

17.

Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K . Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015; 22(6):755-63. PMC: 4475452. DOI: 10.1016/j.chembiol.2015.05.009. View

18.

Erlanson D, Fesik S, Hubbard R, Jahnke W, Jhoti H . Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016; 15(9):605-619. DOI: 10.1038/nrd.2016.109. View

19.

Fischer E, Bohm K, Lydeard J, Yang H, Stadler M, Cavadini S . Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014; 512(7512):49-53. PMC: 4423819. DOI: 10.1038/nature13527. View

20.

Ho S, Clipstone N, Timmermann L, Northrop J, GRAEF I, Fiorentino D . The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996; 80(3 Pt 2):S40-5. DOI: 10.1006/clin.1996.0140. View